VYNE Therapeutics (NASDAQ:VYNE) Releases Earnings Results, Beats Estimates By $0.10 EPS

VYNE Therapeutics (NASDAQ:VYNE) issued its quarterly earnings results on Friday. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.10, FiscalAI reports. The company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.20 million. VYNE Therapeutics had a negative return on equity of 74.86% and a negative net margin of 4,646.14%.

VYNE Therapeutics Trading Down 0.1%

Shares of VYNE opened at $0.67 on Friday. The business’s 50-day moving average price is $0.62 and its 200 day moving average price is $0.54. The stock has a market capitalization of $22.32 million, a P/E ratio of -0.86 and a beta of 2.00. VYNE Therapeutics has a 1-year low of $0.28 and a 1-year high of $1.96.

Analyst Ratings Changes

A number of brokerages have recently commented on VYNE. Wall Street Zen raised VYNE Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of VYNE Therapeutics in a report on Monday, May 4th. Three analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Reduce”.

Hedge Funds Weigh In On VYNE Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. KVP Capital Advisors LP purchased a new position in VYNE Therapeutics in the 4th quarter worth about $290,000. XTX Topco Ltd purchased a new position in VYNE Therapeutics in the 4th quarter worth about $46,000. ADAR1 Capital Management LLC purchased a new position in VYNE Therapeutics in the 4th quarter worth about $147,000. Anson Funds Management LP purchased a new position in VYNE Therapeutics in the 4th quarter worth about $739,000. Finally, Nantahala Capital Management LLC purchased a new position in VYNE Therapeutics in the 4th quarter worth about $580,000. Hedge funds and other institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.